Elsevier, The Lancet Psychiatry, Volume 10, July 2023
Background: The role of alcohol use in the development of depression is unclear. We aimed to investigate whether alcohol dependence, but not high frequency or quantity of consumption, during adolescence increased the risk of depression in young adulthood. Methods: In this prospective cohort study, we included adolescents who were born to women recruited to the Avon Longitudinal Study of Parents and Children in Avon, UK, with delivery dates between April 1, 1991, and Dec 31, 1992.
Elsevier,
American Journal of Clinical Nutrition, Volume 118, July 2023
The authors of this paper conclude that reducing Ultraprocessed Drink Consumption could lower environmental impact and all-cause mortality risk; however, this was not shown for Ultraprocessed Foods. When categorizing food consumption by their degree of processing, trade-offs are observed for human and planetary health aspects.
Press Release
RELX SDG Inspiration Day 2023: Fostering Global Cooperation to Advance Biodiversity
The event saw spirited discussions on how leaders, businesses, organisations, and people can help protect nature and biodiversity.
Over 1500 people gathered virtually on 13 June 2023 for the ninth RELX SDG Inspiration Day: "Not Too Late for Nature: Biodiversity and the UN Sustainable Development Goals."
Elsevier,
The Lancet HIV, 2023, ISSN 2352-3018, https://doi.org/10.1016/S2352-3018(23)00106-6.
This paper reviews the unique perspective that Indigenous People have on the HIV/AIDS epidemic, and the interactions between Indigenous Identities and HIV. The authors call for a human rights based approach to ending the HIV epidemic among Indigenous Peoples.
In a first-of-its-kind report, learn which companies are the world’s leading patent owners with the potential to drive transformative innovation toward the United Nations Sustainable Development Goals (SDGs).
Elsevier,
The Lancet Gastroenterology and Hepatology, Volume 8, July 2023
This Article supports SDG 3 by analysing peripartum antiviral prophylaxis for hepatitis B in 110 countries, finding that it could be beneficial in averting both neonatal hepatitis B infections and DALYS, and that it might be cost-effective depending on how it is implemented and the associated diagnostic costs.
